MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Verastem DSO Ratio 2011-2026 | VSTM
Annual DSO Ratio Verastem
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 38.5 | 67.1 | 5.7 | 52.8 | 4.18 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 67.1 | 4.18 | 33.6 |
Quarterly DSO Ratio Verastem
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 35.7 | - | - | - | - | 46.1 | - | - | - | - | - | - | 3.6 | 48.8 | 55.5 | - | 13.3 K | 146 | 61.9 | 43.1 | 0.28 | 5.06 | 24.9 | 63.7 | 25.5 | 73.4 | 77.3 | 23.1 | 1.8 | 2.79 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 K | 0.28 | 736 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 9.32 | 1.19 % | $ 603 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 0.89 | 0.51 % | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.48 | 1.26 % | $ 3.73 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Innoviva
INVA
|
24.6 | $ 23.09 | 0.17 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 2.95 | -1.34 % | $ 4.86 M |  Israel |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Aquestive Therapeutics
AQST
|
103 | $ 4.08 | 0.74 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 22.96 | 2.64 % | $ 2.92 B | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 15.11 | -4.97 % | $ 48.3 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.44 | 1.77 % | $ 383 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.76 | -0.42 % | $ 27.9 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 45.14 | 1.01 % | $ 12.3 B | USA |